CardioInsight's Non-Invasive 3D Cardiac Mapping to be Featured at the 2014 Heart Rhythm Society Scientific Sessions - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
CardioInsight's Non-Invasive 3D Cardiac Mapping to be Featured at the 2014 Heart Rhythm Society Scientific Sessions


CardioInsight's Non-Invasive 3D Cardiac Mapping to be Featured at the 2014 Heart Rhythm Society Scientific Sessions

PR Newswire

CLEVELAND, May 5, 2014 /PRNewswire-USNewswire/ -- CardioInsight Technologies, Inc., the leading developer of non-invasive electrocardiographic mapping technology, is excited to announce that its ECVUE™* system will be featured at the Rhythm Theatre Symposium and in 17 abstract presentations at the upcoming 2014 Heart Rhythm Society Annual Scientific Sessions in San Francisco, California.  

CardioInsight Technologies, Inc. logo

The Rhythm Theatre Symposium highlights promising results from European clinical studies using the Company's non-invasive mapping for persistent atrial fibrillation in over 300 patients.  The symposium, chaired by Dr. Francis Marchlinski (University of Pennsylvania Medical Center), will be held on Wednesday, May 7 th from 6:15 to 7:15 PM in Rhythm Theatre #2, and include presentations from Dr. Douglas Packer (Mayo Clinic), Dr. Michel Haissaguerre (CHU Bordeaux) and Dr. Sebastien Knecht (CHU Brugmann, Brussels).  Topics include:

  • Clinical AF Mapping:  Back to the Future (Douglas L. Packer, M.D.)
  • A Practical Approach to AF Mapping:  AFACART EU Multicenter Study Results (Sebastien Knecht, M.D.)
  • The Bordeaux Experience (Michel Haissaguerre, M.D.)
  • Common Clinical Questions & Practical Considerations (Francis Marchlinski, M.D.)

"The ECVUE System and its unique non-invasive cardiac mapping clinical applications has been clinically proven in nearly 1,000 patients and in over 100 publications," stated Patrick Wethington, CardioInsight's President and CEO.  "CardioInsight, in partnership with leading EP clinical centers, is honored to advance both the science and clinical utility of the ECVUE system as reflected by the 17 abstracts and symposia presentations at the upcoming 2014 HRS Conference."

The abstract presentations, from leading medical centers, will demonstrate the broad clinical utility of the ECVUE system in mapping atrial and ventricular arrhythmias, as well as mapping for cardiac resynchronization therapy for heart failure.

* EC VUE is not yet cleared or approved for use by the FDA.   EC VUE has received CE Mark.

About CardioInsight Technologies Inc.

CardioInsight is developing and commercially validating a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart.  The images help physicians map electrical disorders of the heart.  The Company's ECVUE™ system non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3D anatomical data obtained from imaging scans.  It then reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart.    

Logo - http://photos.prnewswire.com/prnh/20121101/DC03452LOGO

SOURCE CardioInsight Technologies Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here